Patriot Financial Group Insurance Agency’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-1,788
Closed -$206K 522
2024
Q3
$206K Hold
1,788
0.03% 462
2024
Q2
$246K Sell
1,788
-70
-4% -$9.6K 0.04% 412
2024
Q1
$256K Buy
1,858
+20
+1% +$2.73K 0.04% 403
2023
Q4
$242K Buy
1,838
+3
+0.2% +$345 0.05% 383
2023
Q3
$206K Buy
+1,835
New +$193K 0.04% 417
2023
Q1
Sell
-2,094
Closed -$250K 480
2022
Q4
$250K Buy
+2,094
New +$245K 0.03% 354
2022
Q3
Sell
-78
Closed -$8K 1382
2022
Q2
$8K Sell
78
-13
-14% -$1.2K ﹤0.01% 1338
2022
Q1
$9K Buy
91
+52
+133% +$4.41K ﹤0.01% 1404
2021
Q4
$3K Sell
39
-50
-56% -$4.6K ﹤0.01% 1868
2021
Q3
$9K Buy
89
+23
+35% +$2.17K ﹤0.01% 1517
2021
Q2
$6K Sell
66
-16
-20% -$1.53K ﹤0.01% 1595
2021
Q1
$8K Sell
82
-22
-21% -$2.31K ﹤0.01% 1430
2020
Q4
$10K Sell
104
-6
-5% -$580 ﹤0.01% 1228
2020
Q3
$11K Buy
110
+5
+5% +$578 ﹤0.01% 1007
2020
Q2
$13K Buy
105
+20
+24% +$2.21K 0.01% 886
2020
Q1
$7K Buy
+85
New +$8.32K ﹤0.01% 980

Other funds holding NBIX

Patriot Financial Group Insurance Agency's NBIX Position: Q4 2024 in Review

Patriot Financial Group Insurance Agency sold out of Neurocrine Biosciences (NBIX) in Q4 2024, closing a stake of 1,788 shares — an estimated $206K sold.

Patriot Financial Group Insurance Agency first reported a position in NBIX in Q1 2020 and held it in 16 quarters. The position peaked at $256K in Q1 2024. 601 funds tracked by Wall St. Rank hold NBIX as of Q4 2024.

  • Patriot Financial Group Insurance Agency reported no remaining Neurocrine Biosciences position as of Q4 2024 after selling out during the quarter.
  • Patriot Financial Group Insurance Agency sold 1,788 Neurocrine Biosciences shares in Q4 2024, an estimated $206K.
  • Patriot Financial Group Insurance Agency first reported a position in Neurocrine Biosciences in Q1 2020 and held it in 16 quarters.
  • Patriot Financial Group Insurance Agency's Neurocrine Biosciences position peaked at $256K in Q1 2024.
  • 601 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2024.

Based on Patriot Financial Group Insurance Agency's 13F filing for Q4 2024, filed 22 Jan 2025.